Investigating how tumor and immune cells interact in HER2-low breast cancer with bone metastasis during treatment.

Spatial single-cell profiling to identify tumor-immune-bone niche features in HER2-low bone metastasis in response to T-DXd treatment.

NIH-funded research Methodist Hospital Research Institute · NIH-11068330

This study is looking at how tumor cells and immune cells work together in patients with HER2-low breast cancer that has spread to the bones, to find out why some people do better with a treatment called T-DXd than others, and it hopes to discover new clues that could improve future treatments.

Quick facts

Grant typeU01 cooperative agreement
Study typeNIH-funded research
Funding institutionMethodist Hospital Research Institute NIH-funded
Lab location1 site (Houston, United States)
Project IDNIH-11068330 on NIH RePORTER

What this research studies

This research focuses on understanding the interactions between tumor cells and immune cells in patients with HER2-low breast cancer that has spread to the bones. By analyzing samples from patients who have received a specific treatment called T-DXd, the study aims to uncover why some patients respond well while others do not. Using advanced techniques like spatial proteomics and single-cell profiling, researchers will explore the unique features of the bone metastasis environment. This could help identify new factors that influence treatment outcomes.

Who could benefit from this research

Good fit: Ideal candidates for this research are patients diagnosed with HER2-low breast cancer who have experienced bone metastasis and are undergoing T-DXd treatment.

Not a fit: Patients with HER2-positive breast cancer or those without bone metastasis may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved treatment strategies for patients with HER2-low breast cancer and bone metastasis.

How similar studies have performed: Previous research has shown promising results in understanding tumor-immune interactions in cancer treatment, suggesting that this approach could yield valuable insights.

Where this research is happening

Houston, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.